Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population

INTRODUCTION: The fluocinolone acetonide (FA) intravitreal implant 0.59 mg (Retisert(®), Bausch + Lomb, Rochester, NY, USA) provides sustained release of FA directly to the vitreous cavity over a prolonged period of time. The purpose of this study was to evaluate the safety and efficacy of a 0.59- a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangwan, Virender S., Pearson, P. Andrew, Paul, Hemanth, Comstock, Timothy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470982/
https://www.ncbi.nlm.nih.gov/pubmed/25502122
http://dx.doi.org/10.1007/s40123-014-0027-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470982/
https://www.ncbi.nlm.nih.gov/pubmed/25502122
http://dx.doi.org/10.1007/s40123-014-0027-6

Ejemplares similares